Category: Uncategorized

This appears to be a move towards in vitro screening of patient subset tissues for new drug candidates, or a 'zero phase' clinical trial, rather than screening in animal disease models. This is another branch, it seems, of the recognition of the power of personalized medicine: patient subpopulations with reduced heterogeneity. Animal models can be poor predictors of clinical efficacy in man, and for many diseases, there are not even such imperfect models. This may also be a technology on the verge of the awesome dream of being able to manufacture human organ in the test tube. http://lnkd.in/CXkW8P View in LinkedIn

CATALUNYA BIOPHARMA CAPITAL GROUP AT LINKEDIN" "" "Dear Members: WE NEED YOUR SMARTS!! Catalunya in Northern Spain is emerging as a new Silicon Valley for entrepreneuring, with opportunities for partnering, mentoring, investing and much more. This may be a useful adjunct to this group. Please come and see how dynamic the region is, and especially, we are interested in your observations about how to grow the industry. Your historical insights would be invaluable. View in LinkedIn

Watch this space! This has far-reaching implications. http://lnkd.in/ai2KM8 View in LinkedIn

CATALUNYA BIOPHARMA CAPITAL GROUP AT LINKEDIN" "" "Dear Members: WE NEED YOUR SMARTS!! Catalunya in Northern Spain is emerging as a new Silicon Valley for entrepreneuring, with opportunities for partnering, mentoring, investing and much more. This may be a useful adjunct to this group. Please come and see how dynamic the region is, and especially, we are interested in your observations about how to grow the industry. Your historical insights would be invaluable. View in LinkedIn

This is an urban myth that needs unpacking. It is predicated on the bloated carrying costs of big pharma. Big pharma has become very inefficient at discovery. Hundreds os small specialty pharma companies exist today that were started by a small Venture Capital cash infusion, and on average the total cash infused to get a drug to Proof of Concept (Phase II) is about 30 million USD. The world is changing. Please do not keep quoting these misleading statistics! http://lnkd.in/FN8CqC View in LinkedIn

CATALUNYA BIOPHARMA CAPITAL GROUP AT LINKEDIN" "" "Dear Members: Catalunya in Northern Spain is emerging as a new Silicon Valley for entrepreneuring, with opportunities for partnering, mentoring, investing and much more. This may be a useful adjunct to this group. Please come and see how dynamic the region is, and especially, we are interested in your observations about how to grow the industry. Your historical insights would be invaluable. View in LinkedIn

HANG ONTO YOUR SEATS!" "" "We will announce in the New Year a new company in Barcelona dedicated to solving these problems. We will also have a survey of members completed in the coming weeks so you can all see your thoughts. Watch this space!! View in LinkedIn

CATALUNYA BIOPHARMA CAPITAL GROUP AT LINKEDIN" "" "Dear Members: Catalunya in Northern Spain is emerging as a new Silicon Valley for entrepreneuring, with opportunities for partnering, mentoring, investing and much more. This may be a useful adjunct to this group. Please come and see how dynamic the region is, and especially, we are interested in your observations about how to grow the industry. Your historical insights would be invaluable. View in LinkedIn

OBVIOUS LOGIC" "" "The other obvious point is this: there is duplication among the young biopharma companies, and like any maturing industry, mergers, acquisitions, strategic alliances and collaborations are critical. I have not seen a lot of companies thinking seriously about this. The time is now! View in LinkedIn

SIMPLE FACT: CAPITAL SHORTFALL" "" "Somebody has probably done the precise calculation but this is a simple back of the envelope estimation: there are (by Biocat's figuring) about 91 biotech and 71 pharma companies in Catalunya. This is 162 companies in this sector. Assuming a very rough $25 M in clinical trial costs to get to Phase II Proof-of-Concept, this a capital need of about $4.0 billion. The capital available in Catalan VC companies is probably no more than 200-300 M, optimistically. The delta is huge. Without external capital, most of these small biopharma companies will not survive. View in LinkedIn